Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up

Cytometry Part B - Clinical Cytometry

Volumn 82 B, Issue 1, 2012, Pages 3-8

  Larsen, Hanne Ø ^a   Roug, Anne S ^a   Just, Tom ^b   Brown, Gordon D ^c   Hokland, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b University of Aberdeen ^*

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

AML; hMICL; immunophenotyping; LAIP; MRD

Indexed keywords

CD34 ANTIGEN; INHIBITORY C TYPE LECTIN LIKE RECEPTOR; LECTIN RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; DISEASE MARKER; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; CELL COUNT; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; LECTINS, C-TYPE; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, MITOGEN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84155172363     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20614     Document Type: Article

References (32)

1. Löwenberg B,. Acute myeloid leukemia: The challenge of capturing disease variety. Hematology Am Soc Hematol Educ Program 2008; 1-11.
2. Grimwade D, Hills RK,. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009; 385-395.
3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
4. Craig FE, Foon KA,. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111: 3941-3967.
5. Haycocks NG, Lawrence L, Cain JW, Zhao XF,. Optimizing antibody panels for efficient and cost-effective flow cytometric diagnosis of acute leukemia. Cytometry B Clin Cytom 2011; 80: 221-229.
6. Al-Mawali A, Gillis D, Hissaria P, Lewis I,. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol 2008; 129: 934-945.
7. Olaru D, Campos L, Flandrin P, Nadal N, Duval A, Chautard S, Guyotat D,. Multiparametric analysis of normal and postchemotherapy bone marrow: Implication for the detection of leukemia-associated immunophenotypes. Cytometry B Clin Cytom 2008; 74: 17-24.
8. Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T, Kern W,. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom 2004; 62: 25-38. (Pubitemid 39463698)
9. Ossenkoppele GJ, van de Loosdrecht AA, Schuurhuis GJ,. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol 2011; 53: 421-436.
10. Al-Mawali A, To L, Gillis D, Hissaria P, Mundy J, Lewis I,. The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia. Int J Lab Hematol 2009; 31: 61-68.
11. Majeti R,. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011; 0: 1009-1019.
12. Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, et al. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 2009; 23: 25-42.
13. Marshall ASJ, Willment JA, Lin H-H, Williams DL, Gordon S, Brown GD,. Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. J Biol Chem 2004; 279: 14792-14802. (Pubitemid 38618868)
14. Marshall ASJ, Willment JA, Pyz E, Dennehy KM, Reid DM, Dri P, Gordon S, Wong SYC, Brown GD,. Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation. Eur J Immunol 2006; 36: 2159-2169. (Pubitemid 44251761)
15. van Rhenen A, Moshaver B, Ossenkoppele GJ, Schuurhuis GJ,. New approaches for the detection of minimal residual disease in acute myeloid leukemia. Curr Hematol Malig Rep 2007; 2: 111-118. (Pubitemid 46732568)
16. van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AWM, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ,. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 2007; 21: 1700-1707. (Pubitemid 47086760)
17. Becker MW, Jordan CT,. Leukemia stem cells in 2010: Current understanding and future directions. Blood Rev 2011; 25: 75-81.
18. van der Pol MA, Feller N, Roseboom M, Moshaver B, Westra G, Broxterman HJ, Ossenkoppele GJ, Schuurhuis GJ,. Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 2003: 88; 983-993. (Pubitemid 37151149)
19. Swerdlow HS,. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer, World Health Organization; 2008. pp 439.
20. Borowitz MJ, Guenther KL, Shults KE, Stelzer GT,. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993; 100: 534-540. (Pubitemid 23346202)
21. Lacombe F, Durrieu F, Briais A, Dumain P, Belloc F, Bascans E, Reiffers J, Boisseau MR, Bernard P,. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 1997; 11: 1878-1886. (Pubitemid 27485133)
22. Béné MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, Lacombe F, Lemez P, Marinov I, Matutes E, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: A consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 2011; 25: 567-574.
23. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010; 115: 1976-1984.
24. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, Woll P, Mead A, Alford KA, Rout R, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011; 19: 138-152.
25. Tomová A, Babusíková O,. Shifts in expression of immunological cell markers in relapsed acute leukemia. Neoplasma 2001; 48: 164-168. (Pubitemid 32678679)
26. Vercauteren SM, Sutherland HJ,. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy 2001; 3: 449-459. (Pubitemid 34784642)
27. Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, Griesinger F, Puhlmann U, Reinhardt D,. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry B Clin Cytom 2005; 63: 1-9. (Pubitemid 40096838)
28. Li X, Du W, Liu W, Li X, Li H, Huang S-A,. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse. APMIS 2010; 118: 353-359.
29. Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T,. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract Res Clin Haematol 2010; 23: 379-390.
30. Al-Mawali A, Gillis D, Lewis I,. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B Clin Cytom 2009; 76: 91-101.
31. Björklund E, Gruber A, Mazur J, MÃrtensson A, Hansson M, Porwit A,. CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients. Int J Hematol 2009; 90: 292-302.
32. Hokland P, Ommen HB,. Towards individualized follow-up in adult acute myeloid leukemia in remission: What is lacking before we can apply minimal residual disease as an integrated tool in clinical decision-making? Blood 2011; 117: 2577-2584.